Patents by Inventor Divyakant S. Desai

Divyakant S. Desai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9358207
    Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: June 7, 2016
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Sanjeev H. Kothari, Divyakant S. Desai
  • Patent number: 9339472
    Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: May 17, 2016
    Assignee: AstraZeneca AB
    Inventors: Divyakant S. Desai, Bing V. Li
  • Publication number: 20140255486
    Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
    Type: Application
    Filed: May 22, 2014
    Publication date: September 11, 2014
    Applicant: AstraZeneca AB
    Inventors: Divyakant S. Desai, Bing V. LI
  • Publication number: 20140120163
    Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 1, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Divyakant S. Desai, Bing V. Li
  • Publication number: 20140079778
    Abstract: The present invention relates to solid, semisolid, or liquid formulations comprising water soluble antioxidants that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf-life storage. The formulations of the present invention prevent or reduce formation of N-formyl impurities (and gelatin crosslinking) during the manufacturing process and/or during shelf-life storage.
    Type: Application
    Filed: January 31, 2012
    Publication date: March 20, 2014
    Applicants: AstraZeneca UK Limited, Bristol-Myers Squibb Company
    Inventors: Ajit Narang, Venkatramana M. Rao, Divyakant S. Desai
  • Patent number: 8628799
    Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: January 14, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Divyakant S. Desai, Bing V. Li
  • Publication number: 20130296337
    Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.
    Type: Application
    Filed: July 10, 2013
    Publication date: November 7, 2013
    Inventors: Sanjeev H. Kothari, Divyakant S. Desai
  • Publication number: 20130224296
    Abstract: The present invention relates to solid, semisolid, or liquid formulations comprising water soluble antioxidants that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf-life storage. The formulations of the present invention prevent or reduce formation of N-formyl impurities (and gelatin cross-linking) during the manufacturing process and/or during shelf-life storage.
    Type: Application
    Filed: September 1, 2011
    Publication date: August 29, 2013
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ajit Narang, Venkatramana M. Rao, Divyakant S. Desai
  • Patent number: 8518421
    Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: August 27, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sanjeev H. Kothari, Divyakant S. Desai
  • Publication number: 20110200672
    Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
    Type: Application
    Filed: April 26, 2011
    Publication date: August 18, 2011
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Divyakant S. Desai, Bing V. Li
  • Patent number: 7951400
    Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: May 31, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Divyakant S. Desai, Bing V. Li
  • Publication number: 20100016448
    Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.
    Type: Application
    Filed: September 14, 2009
    Publication date: January 21, 2010
    Inventors: SANJEEV KOTHARI, DIVYAKANT S. DESAI
  • Patent number: 7507768
    Abstract: An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the metformin is compressible, if necessary. A method for treating diabetes is also provided employing the above formulation.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: March 24, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Danping Li, Lawan Phusanti, Divyakant S. Desai
  • Patent number: 7183321
    Abstract: An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the metformin is compressible, if necessary. A method for treating diabetes is also provided employing the above formulation.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: February 27, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Danping Li, Lawan Phusanti, Divyakant S. Desai
  • Publication number: 20030139461
    Abstract: An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the metformin is compressible, if necessary. A method for treating diabetes is also provided employing the above formulation.
    Type: Application
    Filed: December 17, 2001
    Publication date: July 24, 2003
    Inventors: Danping Li, Lawan Phusanti, Divyakant S. Desai
  • Patent number: 5994348
    Abstract: Pharmaceutical compositions containing irbesartan, alone or in combination with a diuretic, providing tablets with a high relative amount of active agent and excellent wetting and disintegration properties.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: November 30, 1999
    Assignee: Sanofi
    Inventors: Cathy C. Ku, Omar L. Sprockel, Beth A. Lang, Divyakant S. Desai
  • Patent number: 5801220
    Abstract: A rapid disintegrating and dispersing composition for thickening liquid waste into a thixotropic gel comprises a polymeric acrylic resin and a colloid-forming mixture of microcrystalline cellulose and sodium carboxymethylcellulose. Additional ingredients preferably used in making a tableted form of the composition include microcrystalline cellulose per se, polyvinylpolypyrrolidone, magnesium stearate and amorphous silica. The tablet is placed in suitable containment means such as a containment bag. The thixotropic properties of the composition enable the gelled waste to be restored to a liquid when small amounts of hand pressure are applied to the waste containment bag, thereby providing a convenient and simple means for disposal.
    Type: Grant
    Filed: November 1, 1995
    Date of Patent: September 1, 1998
    Assignee: E.R. Squibb & Sons, Inc.
    Inventors: Divyakant S. Desai, Ajit B. Thakur